Market News & Trends
CLINiLABS Opens Phase I Unit
Clinilabs, an early phase and specialty CRO that provides clinical drug development services to the pharmaceutical industry, recently announced it has opened a second Phase…
Royalty Pharma Raises $600 Million of Debt
Royalty Pharma recently announced it has successfully issued $600 million of incremental Term Loan B debt through RPI Finance Trust (RPIFT), bringing total debt outstanding…
Takeda's MAA Filing Triggers a $10-Million Milestone
Furiex Pharmaceuticals, Inc. recently confirmed that Takeda Global Research & Development Centre (Europe) Ltd. received confirmation on the acceptance of the submission of a Marketing…
Tranzyme Pharma & Norgine Announce Top-Line Data
Tranzyme Pharma and Norgine B.V. recently announced top-line results of the primary analysis of ULISES 008, the second of two Phase III pivotal trials evaluating…
Zurex Pharma Inc. Secures $6.2-Million Financing
Zurex Pharma, Inc. recently announced it has raised $6.2 million in Series A financing, led by Baird Venture Partners and the State of Wisconsin Investment…
5/23/2012
Agilent to Acquire Cancer Diagnostic Company for $2.2 Billion Agilent Technologies Inc. and EQT, the Sweden-based private equity group, recently announced the execution of a…
Agilent to Acquire Cancer Diagnostic Company for $2.2 Billion
Agilent Technologies Inc. and EQT, the Sweden-based private equity group, recently announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based…
IntelliCap Provides Reliable & Accurate Delivery
Medimetrics, recently certified to ISO 13485, has successfully developed the IntelliCap system, specifically designed to target delivery of small molecule drugs and biologics to the…
Newron & Zambon Enter Strategic Collaboration & License Agreement
Newron Pharmaceuticals S.p.A. recently announced it has executed with Zambon a strategic collaboration and license agreement for Newron's lead compound safinamide. In aggregate, the total…
Piramal Healthcare to Buy US Drug Data Firm for $635 Million
Piramal Healthcare Limited recently announced it has agreed to acquire Decision Resources Group for a consideration of approximately $635 million. Decision Resources Group provides high-quality,…
Ra Pharma Closes $8.6-Million Second Tranche of $27 Million Series A
Ra Pharmaceuticals recently announced it is pursuing hereditary angioedema (HAE) as a lead program, leveraging the company's proprietary Cyclomimetic drug discovery and development platform. HAE…
Relay Technology Launches Intelligence & Data Visualization Solution
Relay Technology Management recently announced the official launch of Business Development Live (BD Live!) - a new unified, real-time data visualization, comparative asset analysis and…
INTAC Technology Combats Misuse of Extended-Release Drugs
During this year's Annual Scientific Meeting of the American Pain Society (May 16-19, 2012, Honolulu, HI), Grunenthal presented results from clinical studies utilizing a product…
Mucosis Announces Positive Data for Mimopath Platform
Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal vaccines are safe and well tolerated as well as able to produce…
Novozymes Now Supplying Hyasis, a Novel Pharmaceutical-Grade HA
Novozymes Biopharma, part of Novozymes A/S, recently announced the first shipment of the company's Bacillus-derived hyaluronic acid, Hyasis, from its newly inaugurated manufacturing facility in…
Nuevolution Receives Milestone Payment From Boehringer Ingelheim
Nuevolution A/S recently announced that it has received a milestone payment derived from its collaboration with Boehringer Ingelheim. The payment was triggered following identification of…
OncoMed Pharmaceuticals Files for $115-Million IPO
OncoMed Pharmaceuticals Inc. recently announced it is seeking $115 million in an initial public stock offering. The Redwood City-based cancer drug developer, one of the…
5/16/2012
Mucosis Announces Positive Data for Mimopath Platform Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal vaccines are safe and well…
Cornerstone to Acquire EKR Therapeutics for $150 Million
Cornerstone Therapeutics Inc. and EKR Therapeutics, Inc. recently announced they have entered into a definitive merger agreement whereby Cornerstone Therapeutics will acquire EKR Therapeutics. The…
5/9/2012
Caisson Biotech Enters Potential $100 Million Agreement Caisson Biotech, L.L.C. recently announced it has entered into a development and license agreement with Novo Nordisk A/S.…
